CLINICAL TRIALS PROFILE FOR TYGACIL
✉ Email this page to a colleague
All Clinical Trials for Tygacil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00481962 ↗ | Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs) | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-02-01 | The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate). | |
| NCT00488345 ↗ | Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 | 2007-12-01 | To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections; complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), or community-acquired pneumonia (CAP). |
| NCT00488488 ↗ | A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting | Completed | Pfizer | 2006-11-01 | To assess the efficacy and safety of Tygacil in the usual German hospital setting. The main goals are: to assess the efficacy of Tygacil under usual care conditions (cure rate); to assess the main side effects observed in daily medical practice (Safety of Tygacil); to determine whether patients are optimally dosed with Tygacil (according to the label) and the proportion of patients receiving a monotherapy versus combination therapy; to observe the potential resistance development against Tygacil in Germany; to determine which antibiotic agents are chosen for a combination therapy with Tygacil; to determine to which antibiotic substance non-responders to Tygacil are switched; to assess the duration of the intravenous therapy with Tygacil and to determine whether and which patients receive an oral antibiotic substance after the therapy with Tygacil; to collect information on profile, comorbidities and characteristics of patients treated with Tygacil. | |
| NCT00600600 ↗ | Tigecycline for Treatment of Rapidly Growing Mycobacteria | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 | 2002-04-01 | To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tygacil
Condition Name
Clinical Trial Locations for Tygacil
Trials by Country
Clinical Trial Progress for Tygacil
Clinical Trial Phase
Clinical Trial Sponsors for Tygacil
Sponsor Name
